Eli Lilly (LLY)
$898.10
0.00 (0.00%)
LLY Stock Quote Delayed 30 Minutes
Biggest Movers in Healthcare Stocks Now – ISRG QCOR NVDQ MDCO
Healthcare stocks remained flat so far on Thursday on Wall Street. NASDAQ:ISRG, NASDAQ:QCOR, NASDAQ:NVDQ, NASDAQ:MDCO, NYSE:LLY, NYSE:FMS, NASDAQ:THOR, NYSE:ZMH, NYSE:SYK, NYSE:BSX, NASDAQ:HZNP, NASDAQ:IRWD, NASDAQ:XLRN, NASDAQ:CLDX, NASDAQ:HALO, NASDAQ:ACAD, NASDAQ:ISIS, NASDAQ:SGMO, NASDAQ:IPXL, NASDAQ:VRTX
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
2,810
Day's Range
-
52-Week Range
$434.34 - $918.50
Dividend & Yield
$4.52 (0.50%)
LLY Stock Predictions, Articles, and Eli Lilly News
The One Stock You Must Sell Now Is Eli Lilly
Eli Lilly's in a position where patents are coming off faster than new products are coming on board, a bad sign for a stock you should sell right now....
5 Pharma Stocks to Buy for Big Dividends
Drugmakers aren't known for big dividends, but the pharmaceutical industry can actually offer something for income investors.
3 Nightmare Stocks of 2013 – JCP BJRI LLY
It's been a rough year for these 3 stocks, as they've underperformed across the board. Is there any chance for a recovery in 2014? Let's find out now
3 Huge Healthcare Trends Can Fatten Your Portfolio
Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities
Q3 Earnings Roundup for Pharmaceutical Stocks
None of the market's major pharmaceutical stocks are in the same boat. Here's the main thing investors need to know about each.
Should I Buy JNJ Stock? 3 Pros, 3 Cons
Johnson & Johnson has had a killer year to so far, but the company faces some headwinds while JNJ stock looks a bit frothy. Should you buy?
5 High-Yield Dividend Stocks for the Fall
Consider these five high-yield dividend stocks to both protect you from near-term volatility and grow your retirement nest egg long-term.
Will MannKind’s Luck Change the Second Time Around?
MannKind's diabetes drug, Afrezza, is back in Phase 3 trials and is showing similar promise. But can it clear the hump to approval ... unlike last time?
Should I Buy Zoetis? 3 Pros, 3 Cons
Animal medicines stock Zoetis has basically been treading water since its IPO. Is it a potential boomer in the making, or should you expect more flat going forward?
Attention Yield Seekers: Now Is Your Chance to Act!
In this low interest rate environment, dividends are still looking great, and these 26 stocks are about to go ex-dividend. Decide how to play them today
5 Megatrend Plays Offering Big Payouts
Megatrend investments usually require years if not decades to play out, but these five particular stocks offer investors some sizable income for waiting.
15 Dividend Stocks to Buy on the Cheap
Here are 15 dividend stocks that I find a great value today based on our fundamental analysis. All provide great yields and solid growth potential
Bulls vs. Bears: Can Biogen Keep Booming?
Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments.
The Best and Worst Mutual Funds of Q1 2013
Healthcare and Japanese stocks were among some of the hottest mutual fund flavors of the year's first quarter, while India and gold lagged behind.
Should I Buy Merck? 3 Pros, 3 Cons
Merck is in the midst of a prolonged downtrend after hitting multiyear highs in 2012. Should you get in, or keep avoiding the Big Pharma stock?
Winners After Novo Nordisk’s Insulin Rejection
Eli Lilly and Sanofi look like the biggest players that are best suited to benefit from Novo Nordisk's diabetes-drug setback, but a smaller player could emerge, too.
5 Pharmaceutical Stocks to Buy Now
This week, five Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
Don’t Get Fooled by This Drugmaker’s Chart
Eli Lilly may look like it is approaching a formidable double-top, but momentum and volume should carry it higher. Get the target for LLY.
A Nice Prop for Stocks in 2013: Buybacks
Like 'em or not, repurchases will at least keep a floor under stocks. And lots of big companies still have billions of dollars in authorizations laying fallow.
